The University of Michigan Comprehensive Cancer Center (UMCCC) is one of the nation's premiere multidisciplinary cancer research programs, with a long Institutional tradition of excellence in patient and population-based research. The Patient and Population Core is a new cancer center core resource that has been developed as a result of UMCCC's strategic planning to meet key needs of cancer center researchers identified through a strategic planning process. Programs in cancer prevention and control, clinical research, and basic science all require enhanced access to annotated patient and population data with accompanying DNA samples In order to continue the cancer center's mission and commitment to achieve innovative research in personalized cancer prevention, diagnosis and treatment. The Patient and Population Core is a resource that collects, catalogs, and stores DNA samples together with highly annotated, linked clinical and epidemiologic Information from cancer patients and representative controls without cancer. Building upon an already established cancer center infrastructure and health-system wide institutional commitment to biobanking, the Patient and Population Core takes advantage of the combined resources of the Michigan Institute for Clinical Health Research (MICHR) Biorepository and the Michigan Clinical Research Unit (MCRU) to provide cancer-specific resources to members of the cancer center, This resource will facilitate environmental, susceptibility, prognostic, and mechanistic studies to be conducted by researchers from various disciplines within the cancer center, as well as provide opportunities for pilot studies and resources for successful grant submissions for translational and molecular epidemiologic research studies, by linking specimen data with questionnaire and medical record data. The overall goal of this core is to further empower our investigators, promote resource sharing, and maximize the value of data and DNA sample collection for research participants, investigators, UMCCC members, and our funding agencies. Since its inception in April 2010, DNA samples and data from 3,910 patients have been established within the Patient and Population Core repository, and 7 cancer center members have accessed DNA samples and data. CCSG funding comprises 36% of the proposed core budget, with the remaining support from charge-backs at rates determined by institution-wide metrics and other institutional support.

Public Health Relevance

The Patient and Population Core is dedicated to providing a biolibrary for cancer researchers to understand the causes and cures of cancer. By creating an exceptional resource that contains both data and biosamples of patients with cancer and healthy individuals at risk of cancer, the Patient and Population Core directly contributes to the public health mission of the University of Michigan Comprehensive Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Verhaegen, Monique E; Mangelberger, Doris; Harms, Paul W et al. (2015) Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol 135:1415-24
Chinn, Steven B; Darr, Owen A; Owen, John H et al. (2015) Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck 37:317-26
Vainshtein, Jeffrey M; Spector, Matthew E; Stenmark, Matthew H et al. (2014) Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:234-9
Castro, Maria G; Candolfi, Marianela; Wilson, Thomas J et al. (2014) Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 14:1241-57
Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9
Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17
VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:
Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64
Ro, Seung-Hyun; Semple, Ian A; Park, Haewon et al. (2014) Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281:3816-27
Stenmark, Matthew H; McHugh, Jonathan B; Schipper, Matthew et al. (2014) Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 88:580-8

Showing the most recent 10 out of 862 publications